Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

J&J prices ketamine-like depression treatment at $590-$885 for two doses

Johnson & Johnson said the company’s new nasal spray depression treatment Spravato will be priced at $590 for a 56-milligram dose and $885 for an 84-milligram dosage.

Read More »

Exclusive: CVS to cover migraine drugs from Teva, Lilly; excludes Amgen

CVS Health Corp. – a top U.S. manager of pharmacy benefits – added new migraine drugs from Teva Pharmaceutical Industries Ltd. and Eli Lilly and Co. to the PBM’s list of covered drugs, excluding a rival treatment from Amgen Inc.

Read More »

Pfizer Cuts 150 Jobs, Along With Broader R&D Reconfigurations

Pfizer is ending five preclinical programs in the biosimilar area and cutting 150 positions in Lake Forest, Illinois and in Chennai, India.

Read More »

7 Biotech Trends to Look Out for in 2019

Here are seven trends most likely to be hitting the news cycle in 2019 according to BioSpace.

Read More »

Impel NeuroPharma Closes $67.5 Million Series D to Advance CNS Portfolio

Seattle-based Impel NeuroPharma closed on a Series D financing totaling $67.5 million, co-led by KKR and Northwest Venture Partners.

Read More »

Mental health crisis could cost the world $16 trillion by 2030

Mental health disorders are on the rise in every country in the world and could cost the global economy up to $16 trillion between 2010 and 2030 if a collective failure to respond is not addressed, according to an expert report.

Read More »

Impatient patients turn to online ‘buyers club’ for new drugs

Frustrated by delays in new medicines reaching their own country, a small but growing number of patients are turning to an online broker that bills itself as a legal version of the Dallas Buyers Club.

Read More »

CDC: 14 Million Americans Will Have Alzheimer’s by 2060

Incidence of Alzheimer’s disease is projected to double in the next 40 years unless a cure or preventive measures are found.

Read More »

Lilly migraine drug wins European panel thumbs-up

A European Medicines Agency panel recommended the approval of U.S. pharmaceutical group Eli Lilly’s migraine treatment, bringing the drug one step closer to being sold in the European Union.

Read More »

Amgen’s Aimovig Starts Strong, Multiple Myeloma Drug Wows at Conference

Amgen unveiled data at a multiple myeloma conference for AMG-420, which targets B-cell maturation antigen (BCMA).

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

April 2019 Focus: Healthcare agency & network profiles, industry overview & awards, and more!

Subscribe

Ad Right Bottom